𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cytoplasmic c-erbB2 and survival in Dukes’ B colorectal carcinoma

✍ Scribed by A. Tannapfel; O. Dworak; U. Mansmann; C. Wittekind

Book ID
108778621
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
444 KB
Volume
27
Category
Article
ISSN
0309-0167

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant chemoimmuno- and immunotherapy
Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: A 7-year follow-up analysis
✍ Dr. Ehtesham A. Abdi; John Hanson; Denise E. Harbora; Donald C. Young; T. Alexan 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

A prospectively randomised controlled clinical trial of adjuvant therapy was undertaken, at a single-centre, population-based cancer institute, in patients with Dukes' stages B2 and C colorectal carcinoma after curative surgery. Between 1976 and 1983, 253 patients were randomised to either control (

The common molecular genetic alterations
The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival
✍ Brett R. Dix; Dr. Peter Robbins; Richie Soong; Deborah Jenner; Anthony K. House; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 638 KB

Abbreviations: DCC, deleted in colon cancer (gene); MCC, mutated in colon cancer (gene); APC, adenomatous polyposis coli (gene); PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single strand conformation polymorphism; ICC, immunocytochemistry; LOH, loss of heter

Active specific immunotherapy of Dukes B
Active specific immunotherapy of Dukes B2and C colorectal carcinoma: Comparison of two doses of the vaccine
✍ J. M. Jessup; C. M. McBride; F. C. Ames; L. Guarda; D. M. Ota; M. M. Romsdahl; R 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 759 KB

The ability of active specific immunotherapy to enhance immune responses to autologous tumor-associated antigens (TAA) and to prolong the disease-free interval was evaluated in patients with Dukes B2 and C colorectal carcinoma who had undergone potentially curative resections. Patients were sensitiz